The Cardiovascular Effects of GLP‐1 Receptor Agonists [PDF]
Cardiovascular Therapeutics, 2010 SUMMARYGlucagon‐like peptide‐1 receptor (GLP‐1R) agonists have been shown to regulate blood glucose concentrations by mechanisms including enhanced insulin synthesis/secretion, suppressed glucagon secretion, slowed gastric emptying, and enhanced satiety.
Okerson, Theodore, Chilton, Robert J
openaire +2 more sources
When intensive insulin therapy (MDi) fails in patients with type 2 diabetes: Switching to GLP-1 receptor agonist versus insulin pump [PDF]
, 2016 Treatment with insulin, alone or with oral or injectable hypoglycemic agents, is becoming increasingly common in patients with type 2 diabetes. However, approximately 40% of patients fail to reach their glycemic targets with the initially prescribed ...
Castaneda, Javier +4 more
core +2 more sources
Metabolic Syndrome Abolishes Glucagon-Like Peptide 1 Receptor Agonist Stimulation of SERCA in Coronary Smooth Muscle [PDF]
, 2015 Metabolic syndrome (MetS) doubles the risk of adverse cardiovascular events. Glucagon-like peptide 1 (GLP-1) receptor agonists induce weight loss, increase insulin secretion, and improve glucose tolerance.
Alloosh, Mouhamad +7 more
core +1 more source
Rate of Homologous Desensitization and Internalization of the GLP-1 Receptor
Molecules, 2016 The glucagon-like peptide-1 receptor (GLP-1R) is an important target in the treatment of type 2 diabetes mellitus. The aim of this study was to compare the rate of agonist stimulated desensitization and internalization of GLP-1R.
Ghina Shaaban +2 more
doaj +1 more source
Novel GLP-1 fusion chimera as potent long acting GLP-1 receptor agonist. [PDF]
PLoS ONE, 2010 GLP-1 has a variety of anti-diabetic effects. However, native GLP-1 is not suitable for therapy of diabetes due to its short half-life (t1/2168 h. Intraperitoneal glucose tolerance test (IPGTT) in mice showed that GLP-1/hIgG2 significantly decreased ...
Qinghua Wang +6 more
doaj +1 more source
The peptide agonist-binding site of the glucagon-like peptide-1 (GLP-1) receptor based on site-directed mutagenesis and knowledge-based modelling [PDF]
, 2016 Glucagon-like peptide-1 (7–36)amide (GLP-1) plays a central role in regulating blood sugar levels and its receptor, GLP-1R, is a target for anti-diabetic agents such as the peptide agonist drugs exenatide and liraglutide.
Adelhorst +50 more
core +1 more source
Distinct Regions in the C-Terminus Required for GLP-1R Cell Surface Expression, Activity and Internalisation [PDF]
, 2015 The glucagon-like peptide-1 (GLP-1) receptor (GLP-1R), an important drug target in the treatment of type 2 diabetes, is a G-protein coupled receptor (GPCR) that mediates insulin secretion by GLP-1.
Venkat Kanamarlapudi
core +1 more source
BMJ Open Diabetes Research & Care, 2019 Introduction This real-world study compared glycemic effectiveness, treatment durability, and treatment costs with canagliflozin 300 mg versus any dose of glucagon-like peptide-1 (GLP-1) receptor agonists in patients with type 2 diabetes mellitus (T2DM ...
Mukul Singhal +5 more
doaj +1 more source
The first successful desensitization protocol in exenatide allergy: a case report
Allergy, Asthma & Clinical Immunology, 2023 Background Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes. To date, few immediate allergic reactions due to GLP-1 receptor agonists were reported.
Osman Ozan Yeğit +6 more
doaj +1 more source
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling [PDF]
, 2013 It has been estimated that approximately 8.4% of the world population currently live with diabetes mellitus and type 2 diabetes is the most common form. Type 2 diabetes increases the risk of complications such as heart attacks, blindness, amputations and
Venkat Kanamarlapudi
core +1 more source